Cogstate Limited (ASX:CGS)
Australia · Delayed Price · Currency is AUD | Market Cap | 425.20M +82.2% |
| Revenue (ttm) | 84.06M +18.8% |
| Net Income | 16.16M +46.7% |
| EPS | 0.09 +44.6% |
| Shares Out | 170.76M |
| PE Ratio | 27.04 |
| Forward PE | 22.89 |
| Dividend | 0.02 (0.80%) |
| Ex-Dividend Date | Aug 27, 2025 |
| Volume | 816,992 |
| Average Volume | 130,665 |
| Open | 2.480 |
| Previous Close | 2.490 |
| Day's Range | 2.470 - 2.520 |
| 52-Week Range | 1.210 - 2.970 |
| Beta | 0.12 |
| RSI | 58.06 |
| Earnings Date | Feb 19, 2026 |
About Cogstate
Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventio... [Read more]
Financial Performance
In fiscal year 2025, Cogstate's revenue was $53.09 million, an increase of 22.25% compared to the previous year's $43.43 million. Earnings were $10.14 million, an increase of 86.15%.
Financial numbers in USD Financial StatementsNews
Cogstate Earnings Call Transcript: H1 2026
Record sales contracts and strong clinical trial growth drove double-digit revenue and earnings increases, with significant expansion in mood, sleep, and neuro segments. Margins are expected to recover in H2, supported by a robust pipeline, technology investment, and a strong cash position.
Cogstate Transcript: AGM 2025
Record financial results were achieved with strong revenue and profit growth, driven by diversification into new CNS indications and strategic partnerships. The Board declared a dividend, renewed the employee equity plan, and outlined continued investment in technology and AI. All resolutions were supported by proxies and no major risks or headwinds were reported.
Cogstate Earnings Call Transcript: H2 2025
Record revenue and profit growth driven by clinical trials and software licensing, with strong margins and cash flow. Strategic Medidata partnership and AI product launches set the stage for further expansion in CNS and psychiatric indications.
Cogstate Transcript: Study Update
A strategic partnership between Cogstate and Medidata is driving innovation in CNS clinical trials through integrated digital cognitive assessments, advanced AI, and operational excellence. The collaboration is expanding into rare diseases and psychiatry, with strong early pipeline growth and industry recognition.
Cogstate Earnings Call Transcript: H1 2025
Record half-year revenue and profit growth driven by clinical trials and efficiency gains, with strong margins and positive cash flow. Strategic partnerships and technology investments are expanding the pipeline, though future contracted revenue declined due to healthcare segment changes.
Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer
Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Cogstate, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief ...
Cogstate Earnings Call Transcript: H2 2024
Revenue grew 7% year-over-year, driven by clinical trials, with profit before tax more than doubling and strong margin improvements. The renegotiated Eisai agreement returned IP control, enabling new opportunities, while the share buyback was suspended to preserve capital for potential acquisitions.
Cogstate Earnings Call Transcript: H1 2024
Cogstate Transcript: Status Update
Cogstate Earnings Call Transcript: H2 2023
Cogstate Earnings Call Transcript: H1 2023
Cogstate Transcript: AGM 2022
Cogstate Earnings Call Transcript: H2 2022
Cogstate Earnings Call Transcript: Q4 2022
Cogstate Announces Formation of Scientific Advisory Board
Leading clinical and scientific experts in neurodegenerative diseases and pharmaceutical research will provide guidance to progress Cogstate's strategy Leading clinical and scientific experts in neuro...